Actively Recruiting
Evaluating the Safety of PI3K-gamma Inhibitor Eganelisib with Azacitidine and Venetoclax in Treating Acute Myeloid Leukemia
Led by Jacqueline Garcia, MD · Updated on 2026-08-26
48
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and preliminary effectiveness of adding eganelisib, a PI3K-gamma inhibitor, to the standard treatment of venetoclax and azacitidine in adults with acute myeloid leukemia AML. This phase 1 trial aims to find the maximum tolerated dose of eganelisib and confirm the recommended dose for further studies. The FDA has approved azacitidine and venetoclax for AML, but not the combination including eganelisib. Participants will receive treatment cycles lasting 28 days, with azacitidine given on days 1 to 7, and venetoclax and eganelisib taken orally days 1 to 28. The trial includes two parts dose escalation to find the right dose of eganelisib, followed by dose expansion at that dose. After treatment ends, participants will have follow-up visits every 4 months for up to one year to monitor survival. During the study, participants will have screening, clinic visits, blood and urine tests, ECGs, and bone marrow biopsies. Researchers will measure the recommended phase 2 dose, monitor adverse events, and assess remission rates and duration. This study is expected to last about two years, with ongoing safety and efficacy assessments throughout and after treatment.
CONDITIONS
Brief Title
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Research Team
J
Jaqueline Garcia, MD
J
Jacqueline Garcia, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here